<DOC>
	<DOCNO>NCT02047500</DOCNO>
	<brief_summary>This multicenter , open-label , Phase 1 , dose escalation trial evaluate safety , tolerability , recommend Phase 2 dose ( RP2D ) TH-302 combination gemcitabine nab-paclitaxel previously untreated subject locally advance unresectable metastatic pancreatic adenocarcinoma .</brief_summary>
	<brief_title>Phase I TH-302 Plus Gemcitabine Plus Nab-Paclitaxel Pancreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Subjects great equal ( &gt; = ) 18 year age locally advance unresectable metastatic pancreatic adenocarcinoma proven histology cytology previously untreated chemotherapy systemic therapy : Radiosensitizing dose 5fluorouracil ; Radiosensitizing dos gemcitabine relapse occur least 6 month completion gemcitabine ; Neoadjuvant chemotherapy relapse occur least 6 month surgical resection ; Adjuvant chemotherapy relapse occur least 6 month completion adjuvant chemotherapy Subjects may measurable nonmeasurable disease accord RECIST 1.1 . Eastern cooperative oncology group ( ECOG ) performance status 0 1 Acceptable hematological status , liver renal function define protocol Other protocol define inclusion criterion could apply Significant cardiac peripheral vascular arterial disease Known brain , leptomeningeal epidural metastasis ( unless treat well control least 3 month ) Severe chronic obstructive pulmonary disease hypoxemia Active , uncontrolled bacterial , viral , fungal infection , require systemic therapy Subjects receive concomitant treatment radiotherapy investigational drug Other protocol define exclusion criterion could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>TH-302</keyword>
	<keyword>Nab-paclitaxel</keyword>
	<keyword>Gemcitabine</keyword>
	<keyword>Evofosfamide</keyword>
</DOC>